Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3711675 | 0.90 | MEN1 (0.33) | MEN1CYP1A2POLBTSHRAPEX1 | |
| SCHEMBL3705812 | 0.79 | — | — | |
| SCHEMBL3708325 | 0.78 | MAOB (0.35) | — | |
| SCHEMBL3707937 | 0.68 | MEN1 (0.31) | MEN1CYP1A2POLBTSHRAPEX1 | |
| SCHEMBL3020157 | 0.62 | OPRM1 (0.33) | — | |
| SCHEMBL3017563 | 0.59 | OPRM1 (0.42) | MEN1KMT2A | |
| SCHEMBL3028373 | 0.58 | SLC6A2 (0.35) | — | |
| SCHEMBL2610424 | 0.58 | HCRTR2 (0.46) | — | |
| SCHEMBL2610423 | 0.57 | HCRTR2 (0.45) | — | |
| SCHEMBL11642526 | 0.57 | CACNA1F (0.36) | MEN1CYP1A2POLBTSHRAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391603-A1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010086251-A1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | WO | disclosed |